Avai Bio (AVAI) Cash from Financing Activities (2018 - 2026)

Avai Bio has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $533299.0 for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 214.91% year-over-year to $533299.0; the TTM figure through Jun 2026 stood at $1.3 million (down 5.87% YoY), while the FY2026 annual figure was $951936.0, down 23.32% from the prior year.
• Cash from Financing Activities came in at $533299.0 for Q2 2026 at Avai Bio, up from $23570.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.0 million in Q1 2022 to a low of -$55248.0 in Q3 2022.
• Average Cash from Financing Activities over 5 years is $292642.0, with a median of $165752.5 recorded in 2023.
• The largest YoY upside for Cash from Financing Activities was 6644.1% in 2022 against a maximum downside of 127.86% in 2022.
• Over 5 years, Cash from Financing Activities stood at -$17665.0 in 2022, then soared by 4091.42% to $705085.0 in 2023, then slumped by 80.76% to $135651.0 in 2024, then jumped by 125.24% to $305534.0 in 2025, then soared by 74.55% to $533299.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $533299.0 in Q2 2026, $23570.0 in Q1 2026, and $305534.0 in Q4 2025.